目的 研究三子止咳胶囊联合吸入用异丙托溴铵溶液治疗慢性支气管炎的临床疗效。方法 选取2018年5月-2019年5月在天津市东丽区东丽医院治疗的120例慢性支气管炎患者，将所有患者随机分为对照组和治疗组，每组各60例。对照组患者雾化吸入吸入用异丙托溴铵溶液，2 mL/次，2次/d。治疗组在对照组基础上口服三子止咳胶囊，2粒/次，3次/d。两组患者持续治疗3个月。观察两组患者临床疗效，比较两组的临床症状缓解时间、肺功能指标、血气指标、血清炎性因子水平、支气管炎的严重程度（BSS）。结果 治疗后，对照组和治疗组的总有效率分别为81.67%、95.00%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组咳嗽、气喘和肺部啰音消失时间明显短于对照组（P<0.05）。治疗后，两组呼吸频率（RR）明显降低，潮气量（VT）、达峰容积比（VPEF/VE）和达峰时间比（tPTEF/tE）显著升高（P<0.05），且治疗组肺功能指标升高较多（P<0.05）。治疗后，两组患者氧分压（pO₂）明显升高，二氧化碳分压（pCO₂）明显降低（P<0.05），且治疗组血气指标改善较明显（P<0.05）。治疗后，两组血清高敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-8（IL-8）水平均显著降低（P<0.05），且治疗组血清hs-CRP、TNF-α和IL-8水平降低较明显（P<0.05）。治疗后，两组BSS评分均显著降低（P<0.05）；并且治疗组BSS评分显著低于对照组（P<0.05）。结论 三子止咳胶囊联合吸入用异丙托溴铵溶液治疗慢性支气管炎具有较好的治疗效果，能改善临床症状和肺功能，调节血气指标，降低血清炎性因子水平。

Objective To study the efficacy of Sanzi Zhike Capsules combined with Ipratropium Bromide Solution for inhalation in treatment of chronic bronchitis. Methods Patients (120 cases) with chronic bronchitis in Tianjin Dongli Hospital from May 2018 to May 2019 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were atomization inhalation Ipratropium Bromide Solution for inhalation, 2 mL/time, twice daily. Patients in the treatment group were po administered with Sanzi Zhike Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and clinical symptom disappearance time, lung function index, blood gas index, serum levels of inflammatory factor, and BSS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 95.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, the disappearance time of cough, asthma, and lung rales in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the RR of the two groups was significantly decreased, but VT, VPEF/VE, and tPTEF/tE were significantly increased (P < 0.05). And the lung function indexes of the treatment group were higher than those of the control group (P < 0.05). After treatment, the pO₂ values of two groups were significantly increased, but the pCO₂ values of two groups were significantly decreased (P < 0.05). And the improvement of blood gas indexes in the treatment group was higher than that in the control group (P < 0.05). After treatment, the serum levels of hs-CRP, TNF-α, and IL-8 in two groups were significantly decreased (P < 0.05). And the serum levels of hs-CRP, TNF-α, and IL-8 in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the BSS scores of two groups were significantly decreased (P < 0.05). And the BSS score of the treatment group was significantly lower than that of the control group (P < 0.05). Conclusion Sanzi Zhike Capsules combined with Ipratropium Bromide Solution for inhalation has clinical curative effect in treatment of chronic bronchitis, can improve the clinical symptoms and pulmonary function, regulate blood gas indexes, and reduce the serum level of inflammatory factors.

R974